Citation

Michael White C. J. Clin. Pharmacol. 2014; 54(3): 245-252.

Affiliation

Professor and Chair Pharmacy Practice, University of Connecticut, Co-Director, HOPE Collaborative Group, University of Connecticut and Hartford Hospital, Hartford, CT, USA.

Copyright

(Copyright © 2014, American College of Clinical Pharmacology, Publisher SAGE Publishing)

DOI

10.1002/jcph.266

PMID

24431106

Abstract

MDMA (3,4-methylenedioxymethamphetamine), is an agent of abuse that has been used by over 16 million Americans. Increased energy, elevated mood, bonding with others, and psychedelic effects are desired effects while liver damage, extended depressed mood, sexual assault, rhabdomyolysis, serotonin syndrome, multiorgan failure, cardiovascular events, arrhythmias, and death are possible adverse effects. These desirable and adverse effects of MDMA are extensions of its fascinating pharmacologic and pharmacokinetic profile. In addition to methamphatemine like effects, MDMA also has mescaline like effects and increases the release of cortisol, oxytocin, and antidiuretic hormone. The desirable effects of MDMA is accentuated by the rave or electronic dance music scene where warm temperatures, vigorous dancing, loud music, and light shows accentuate some of the responses. However, the same environment increases the risk of certain harms. Knowledge of the constellation of these factors is needed for education, prevention of harm, and treatment. The Journal of Clinical Pharmacology.

Language: en